Cantor Fitzgerald Reiterates Overweight on Amicus Therapeutics, Maintains $22 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska reiterated an Overweight rating on Amicus Therapeutics (NASDAQ:FOLD) and maintained a $22 price target.
February 29, 2024 | 6:47 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst Kristen Kluska reiterated an Overweight rating on Amicus Therapeutics and maintained a $22 price target.
The reiteration of an Overweight rating and the maintenance of a $22 price target by a reputable analyst could signal confidence in Amicus Therapeutics' future performance, potentially influencing investor sentiment positively in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100